Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women

Ulrike I. Mödder, Matthew M. Roforth, Kelley Hoey, Louise K. McCready, James M. Peterson, David G Monroe, Merry Jo Oursler, Sundeep Khosla

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Decreases in estrogen levels contribute not only to early postmenopausal bone loss but also to bone loss with aging. While estrogen is critical for the maintenance of bone formation, the mechanism(s) of this effect remain unclear. Thus, we assessed the effects of 4. months of transdermal estradiol treatment (0.05. mg/day) of postmenopausal women as compared to no treatment (n = 16 per group) on the expression of genes in pre-specified pathways in freshly isolated bone marrow osteoprogenitor cells (hematopoietic lineage [lin]-/Stro1+). We also evaluated whether estrogen treatment modulated peripheral blood or bone marrow plasma levels of the Wnt antagonists, sclerostin and DKK1, as well as serotonin, OPG, RANKL, adiponectin, oxytocin, and inflammatory cytokines (TNFα, IL-1β, and IL-6), as each of these molecules have recently been shown to play an important role in regulating osteoblast function and/or being responsive to estrogen. We observed a significant decrease in the expression of several proliferation markers (cyclin B1, cyclin E1, E2F1) and increase in adhesion molecules (N-cadherin) in bone marrow lin-/Stro1+ cells from estrogen-treated compared to control women. None of the peripheral blood or bone marrow plasma marker levels differed between the two groups, with the exception of sclerostin levels, which were significantly lower in the estrogen-treated as compared to the control women in peripheral serum (by 32%, P = 0.009) and in bone marrow plasma (by 34%, P = 0.017). There were significant differences in bone marrow versus peripheral plasma levels of several factors: sclerostin and OPG levels were higher in bone marrow as compared to peripheral plasma, whereas serotonin and adiponectin levels were higher in peripheral as compared to bone marrow plasma. In summary, our data directly assessing possible regulation by estrogen of osteoprogenitor cells in humans indicate that, consistent with previous studies in mice, estrogen suppresses the proliferation of human bone marrow lin-/Stro1+ cells, which likely represent early osteoprogenitor cells. Further animal and human studies are needed to define the role of the changes we observed in mRNAs for adhesion molecules in these cells and in local sclerostin production in bone in mediating the effects of estrogen on bone metabolism in humans.

Original languageEnglish (US)
Pages (from-to)202-207
Number of pages6
JournalBone
Volume49
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Estrogens
Cytokines
Bone Marrow
Bone and Bones
Adiponectin
Serotonin
Cyclin B1
Postmenopausal Osteoporosis
Cyclins
Cell Adhesion Molecules
Cell Lineage
Oxytocin
Cadherins
Osteoblasts
Interleukin-1
Osteogenesis
Bone Marrow Cells
Estradiol
Interleukin-6
Therapeutics

Keywords

  • Cytokines
  • Estrogen
  • Osteoporosis
  • Osteoprogenitor cells
  • Postmenopausal women

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. / Mödder, Ulrike I.; Roforth, Matthew M.; Hoey, Kelley; McCready, Louise K.; Peterson, James M.; Monroe, David G; Oursler, Merry Jo; Khosla, Sundeep.

In: Bone, Vol. 49, No. 2, 08.2011, p. 202-207.

Research output: Contribution to journalArticle

Mödder, Ulrike I. ; Roforth, Matthew M. ; Hoey, Kelley ; McCready, Louise K. ; Peterson, James M. ; Monroe, David G ; Oursler, Merry Jo ; Khosla, Sundeep. / Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. In: Bone. 2011 ; Vol. 49, No. 2. pp. 202-207.
@article{576dea3735c24249b144372141273fdc,
title = "Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women",
abstract = "Decreases in estrogen levels contribute not only to early postmenopausal bone loss but also to bone loss with aging. While estrogen is critical for the maintenance of bone formation, the mechanism(s) of this effect remain unclear. Thus, we assessed the effects of 4. months of transdermal estradiol treatment (0.05. mg/day) of postmenopausal women as compared to no treatment (n = 16 per group) on the expression of genes in pre-specified pathways in freshly isolated bone marrow osteoprogenitor cells (hematopoietic lineage [lin]-/Stro1+). We also evaluated whether estrogen treatment modulated peripheral blood or bone marrow plasma levels of the Wnt antagonists, sclerostin and DKK1, as well as serotonin, OPG, RANKL, adiponectin, oxytocin, and inflammatory cytokines (TNFα, IL-1β, and IL-6), as each of these molecules have recently been shown to play an important role in regulating osteoblast function and/or being responsive to estrogen. We observed a significant decrease in the expression of several proliferation markers (cyclin B1, cyclin E1, E2F1) and increase in adhesion molecules (N-cadherin) in bone marrow lin-/Stro1+ cells from estrogen-treated compared to control women. None of the peripheral blood or bone marrow plasma marker levels differed between the two groups, with the exception of sclerostin levels, which were significantly lower in the estrogen-treated as compared to the control women in peripheral serum (by 32{\%}, P = 0.009) and in bone marrow plasma (by 34{\%}, P = 0.017). There were significant differences in bone marrow versus peripheral plasma levels of several factors: sclerostin and OPG levels were higher in bone marrow as compared to peripheral plasma, whereas serotonin and adiponectin levels were higher in peripheral as compared to bone marrow plasma. In summary, our data directly assessing possible regulation by estrogen of osteoprogenitor cells in humans indicate that, consistent with previous studies in mice, estrogen suppresses the proliferation of human bone marrow lin-/Stro1+ cells, which likely represent early osteoprogenitor cells. Further animal and human studies are needed to define the role of the changes we observed in mRNAs for adhesion molecules in these cells and in local sclerostin production in bone in mediating the effects of estrogen on bone metabolism in humans.",
keywords = "Cytokines, Estrogen, Osteoporosis, Osteoprogenitor cells, Postmenopausal women",
author = "M{\"o}dder, {Ulrike I.} and Roforth, {Matthew M.} and Kelley Hoey and McCready, {Louise K.} and Peterson, {James M.} and Monroe, {David G} and Oursler, {Merry Jo} and Sundeep Khosla",
year = "2011",
month = "8",
doi = "10.1016/j.bone.2011.04.015",
language = "English (US)",
volume = "49",
pages = "202--207",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women

AU - Mödder, Ulrike I.

AU - Roforth, Matthew M.

AU - Hoey, Kelley

AU - McCready, Louise K.

AU - Peterson, James M.

AU - Monroe, David G

AU - Oursler, Merry Jo

AU - Khosla, Sundeep

PY - 2011/8

Y1 - 2011/8

N2 - Decreases in estrogen levels contribute not only to early postmenopausal bone loss but also to bone loss with aging. While estrogen is critical for the maintenance of bone formation, the mechanism(s) of this effect remain unclear. Thus, we assessed the effects of 4. months of transdermal estradiol treatment (0.05. mg/day) of postmenopausal women as compared to no treatment (n = 16 per group) on the expression of genes in pre-specified pathways in freshly isolated bone marrow osteoprogenitor cells (hematopoietic lineage [lin]-/Stro1+). We also evaluated whether estrogen treatment modulated peripheral blood or bone marrow plasma levels of the Wnt antagonists, sclerostin and DKK1, as well as serotonin, OPG, RANKL, adiponectin, oxytocin, and inflammatory cytokines (TNFα, IL-1β, and IL-6), as each of these molecules have recently been shown to play an important role in regulating osteoblast function and/or being responsive to estrogen. We observed a significant decrease in the expression of several proliferation markers (cyclin B1, cyclin E1, E2F1) and increase in adhesion molecules (N-cadherin) in bone marrow lin-/Stro1+ cells from estrogen-treated compared to control women. None of the peripheral blood or bone marrow plasma marker levels differed between the two groups, with the exception of sclerostin levels, which were significantly lower in the estrogen-treated as compared to the control women in peripheral serum (by 32%, P = 0.009) and in bone marrow plasma (by 34%, P = 0.017). There were significant differences in bone marrow versus peripheral plasma levels of several factors: sclerostin and OPG levels were higher in bone marrow as compared to peripheral plasma, whereas serotonin and adiponectin levels were higher in peripheral as compared to bone marrow plasma. In summary, our data directly assessing possible regulation by estrogen of osteoprogenitor cells in humans indicate that, consistent with previous studies in mice, estrogen suppresses the proliferation of human bone marrow lin-/Stro1+ cells, which likely represent early osteoprogenitor cells. Further animal and human studies are needed to define the role of the changes we observed in mRNAs for adhesion molecules in these cells and in local sclerostin production in bone in mediating the effects of estrogen on bone metabolism in humans.

AB - Decreases in estrogen levels contribute not only to early postmenopausal bone loss but also to bone loss with aging. While estrogen is critical for the maintenance of bone formation, the mechanism(s) of this effect remain unclear. Thus, we assessed the effects of 4. months of transdermal estradiol treatment (0.05. mg/day) of postmenopausal women as compared to no treatment (n = 16 per group) on the expression of genes in pre-specified pathways in freshly isolated bone marrow osteoprogenitor cells (hematopoietic lineage [lin]-/Stro1+). We also evaluated whether estrogen treatment modulated peripheral blood or bone marrow plasma levels of the Wnt antagonists, sclerostin and DKK1, as well as serotonin, OPG, RANKL, adiponectin, oxytocin, and inflammatory cytokines (TNFα, IL-1β, and IL-6), as each of these molecules have recently been shown to play an important role in regulating osteoblast function and/or being responsive to estrogen. We observed a significant decrease in the expression of several proliferation markers (cyclin B1, cyclin E1, E2F1) and increase in adhesion molecules (N-cadherin) in bone marrow lin-/Stro1+ cells from estrogen-treated compared to control women. None of the peripheral blood or bone marrow plasma marker levels differed between the two groups, with the exception of sclerostin levels, which were significantly lower in the estrogen-treated as compared to the control women in peripheral serum (by 32%, P = 0.009) and in bone marrow plasma (by 34%, P = 0.017). There were significant differences in bone marrow versus peripheral plasma levels of several factors: sclerostin and OPG levels were higher in bone marrow as compared to peripheral plasma, whereas serotonin and adiponectin levels were higher in peripheral as compared to bone marrow plasma. In summary, our data directly assessing possible regulation by estrogen of osteoprogenitor cells in humans indicate that, consistent with previous studies in mice, estrogen suppresses the proliferation of human bone marrow lin-/Stro1+ cells, which likely represent early osteoprogenitor cells. Further animal and human studies are needed to define the role of the changes we observed in mRNAs for adhesion molecules in these cells and in local sclerostin production in bone in mediating the effects of estrogen on bone metabolism in humans.

KW - Cytokines

KW - Estrogen

KW - Osteoporosis

KW - Osteoprogenitor cells

KW - Postmenopausal women

UR - http://www.scopus.com/inward/record.url?scp=79958770416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958770416&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2011.04.015

DO - 10.1016/j.bone.2011.04.015

M3 - Article

C2 - 21550429

AN - SCOPUS:79958770416

VL - 49

SP - 202

EP - 207

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -